CLORAZEPATE DIPOTASSIUM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for clorazepate dipotassium and what is the scope of patent protection?
Clorazepate dipotassium
is the generic ingredient in four branded drugs marketed by Able, Am Therap, Dash Pharms, Dava Pharms Inc, Gd Searle Llc, Purepac Pharm, Quantum Pharmics, Rising, Usl Pharma, Warner Chilcott, Watson Labs, Ajenat Pharms, Aurobindo Pharma, Aurolife Pharma Llc, Corepharma, Lederle, Novitium Pharma, Sun Pharm Inds Ltd, Taro, and Alra, and is included in sixty-two NDAs. Additional information is available in the individual branded drug profile pages.There are seven drug master file entries for clorazepate dipotassium. Seven suppliers are listed for this compound.
Summary for CLORAZEPATE DIPOTASSIUM
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 20 |
| NDAs: | 62 |
| Drug Master File Entries: | 7 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 18 |
| Clinical Trials: | 2 |
| Patent Applications: | 661 |
| Drug Prices: | Drug price trends for CLORAZEPATE DIPOTASSIUM |
| What excipients (inactive ingredients) are in CLORAZEPATE DIPOTASSIUM? | CLORAZEPATE DIPOTASSIUM excipients list |
| DailyMed Link: | CLORAZEPATE DIPOTASSIUM at DailyMed |
Recent Clinical Trials for CLORAZEPATE DIPOTASSIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Ranbaxy Laboratories Limited | N/A |
Pharmacology for CLORAZEPATE DIPOTASSIUM
| Drug Class | Benzodiazepine |
Medical Subject Heading (MeSH) Categories for CLORAZEPATE DIPOTASSIUM
US Patents and Regulatory Information for CLORAZEPATE DIPOTASSIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alra | GEN-XENE | clorazepate dipotassium | TABLET;ORAL | 071788-001 | Apr 26, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Dava Pharms Inc | CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium | CAPSULE;ORAL | 071743-001 | Dec 14, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurolife Pharma Llc | CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium | TABLET;ORAL | 072514-002 | May 11, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Able | CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium | TABLET;ORAL | 071781-001 | Jun 26, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Taro | CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium | TABLET;ORAL | 075731-002 | Apr 27, 2000 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alra | GEN-XENE | clorazepate dipotassium | TABLET;ORAL | 071787-001 | Apr 26, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurolife Pharma Llc | CLORAZEPATE DIPOTASSIUM | clorazepate dipotassium | TABLET;ORAL | 072514-003 | May 11, 1990 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CLORAZEPATE DIPOTASSIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-006 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-007 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE SD | clorazepate dipotassium | TABLET;ORAL | 017105-004 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE SD | clorazepate dipotassium | TABLET;ORAL | 017105-005 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | TABLET;ORAL | 017105-008 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| Ajenat Pharms | TRANXENE | clorazepate dipotassium | CAPSULE;ORAL | 017105-003 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
